We serve Chemical Name:6-Chloro-2,3-difluorobenzaldehyde CAS:797791-33-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Chloro-2,3-difluorobenzaldehyde
CAS.NO:797791-33-4
Synonyms:9758144;6-Chloro-2,3-difluorobenzaldehyde;VHR BG EF FF;Benzaldehyde, 6-chloro-2,3-difluoro-;Benzaldehyde,6-chloro-2,3-difluoro
Molecular Formula:C7H3ClF2O
Molecular Weight:176.548
HS Code:2913000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:205.6±35.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.536
PSA:17.07000
Exact Mass:175.984055
LogP:2.15
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 9758144 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzaldehyde,6-chloro-2,3-difluoro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9758144 Use and application,Benzaldehyde, 6-chloro-2,3-difluoro- technical grade,usp/ep/jp grade.
Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 6-Chloro-2,3-difluorobenzaldehyde manufacturer Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 6-Chloro-2,3-difluorobenzaldehyde supplier ��The number of confirmed cases of coronavirus in Taiwan is not higher than in most countries affected,�� Mr. Wu said. ��Other than China, no other country, no other country has had its flight banned by Italy.�� 6-Chloro-2,3-difluorobenzaldehyde vendor We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 6-Chloro-2,3-difluorobenzaldehyde factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.
